New hope for kidney cancer: experimental drug targets tumor growth
NCT ID NCT04169711
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-stage trial tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had worsened after at least two prior treatments. The goal was to find a safe dose and see if the drug could help control the disease. Participants received injections of the drug, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Aurora, Colorado, 80045, United States
-
Research Site 2
Las Vegas, Nevada, 89169, United States
-
Research Site 4
Nashville, Tennessee, 37232, United States
-
Research Site 5
Dallas, Texas, 75390, United States
-
Research Site 6
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.